OBJECTIVES: To assess the effect of two similar olive oils, but with differences in their phenolic compounds (powerful antioxidant compounds), on inflammatory markers in stable coronary heart disease patients. DESIGN:Placebo-controlled, crossover, randomized trial. SETTING:Cardiology Department of Hospital del Mar and Institut Municipal d'Investigació Mèdica (Barcelona). SUBJECTS:Twenty-eight stable coronary heart disease patients. INTERVENTIONS: A raw daily dose of 50 ml of virgin and refined olive oil (ROO) was sequentially administered over two periods of 3-weeks, preceded by 2-week washout periods in which ROO was used. RESULTS:Interleukin-6 (P<0.002) and C-reactive protein (P=0.024) decreased after virgin olive oil intervention. No changes were observed in soluble intercellular and vascular adhesion molecules, glucose and lipid profile. CONCLUSIONS: Consumption of virgin olive oil, could provide beneficial effects in stable coronary heart disease patients as an additional intervention to the pharmacological treatment.
RCT Entities:
OBJECTIVES: To assess the effect of two similar olive oils, but with differences in their phenolic compounds (powerful antioxidant compounds), on inflammatory markers in stable coronary heart diseasepatients. DESIGN: Placebo-controlled, crossover, randomized trial. SETTING: Cardiology Department of Hospital del Mar and Institut Municipal d'Investigació Mèdica (Barcelona). SUBJECTS: Twenty-eight stable coronary heart diseasepatients. INTERVENTIONS: A raw daily dose of 50 ml of virgin and refined olive oil (ROO) was sequentially administered over two periods of 3-weeks, preceded by 2-week washout periods in which ROO was used. RESULTS: Interleukin-6 (P<0.002) and C-reactive protein (P=0.024) decreased after virgin olive oil intervention. No changes were observed in soluble intercellular and vascular adhesion molecules, glucose and lipid profile. CONCLUSIONS: Consumption of virgin olive oil, could provide beneficial effects in stable coronary heart diseasepatients as an additional intervention to the pharmacological treatment.
Authors: Miguel Á Martínez-González; Miguel Ruiz-Canela; Adela Hruby; Liming Liang; Antonia Trichopoulou; Frank B Hu Journal: J Nutr Date: 2015-04-01 Impact factor: 4.798
Authors: Jennifer K Lee; Polan T Santos; May W Chen; Caitlin E O'Brien; Ewa Kulikowicz; Shawn Adams; Henry Hardart; Raymond C Koehler; Lee J Martin Journal: J Neuropathol Exp Neurol Date: 2021-01-20 Impact factor: 3.685
Authors: C Santangelo; C Filesi; R Varì; B Scazzocchio; T Filardi; V Fogliano; M D'Archivio; C Giovannini; A Lenzi; S Morano; R Masella Journal: J Endocrinol Invest Date: 2016-06-25 Impact factor: 4.256
Authors: M A Martínez-González; C de la Fuente-Arrillaga; J M Nunez-Cordoba; F J Basterra-Gortari; J J Beunza; Z Vazquez; S Benito; A Tortosa; M Bes-Rastrollo Journal: BMJ Date: 2008-05-29
Authors: Erin L Richman; Stacey A Kenfield; Jorge E Chavarro; Meir J Stampfer; Edward L Giovannucci; Walter C Willett; June M Chan Journal: JAMA Intern Med Date: 2013-07-22 Impact factor: 21.873